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Abstract Injuries of the Achilles tendon are relatively common with potentially devastating outcomes. Healing Achilles
tendons form a fibrovascular scar resulting in a tendon which
may be mechanically weaker than the native tendon. The
resulting strength deficit causes a high risk for reinjury and
other complications. Treatments using biologics aim to restore
the normal properties of the native tendon and reduce the risk
of rerupture and maximize tendon function. The purpose of
this review was to summarize the current findings of various
therapies using biologics in an attempt to improve the prognosis of Achilles tendon ruptures and tendinopathies. A
PubMed search was performed using specific search terms.
The search was open for original manuscripts and review papers limited to publication within the last 10 years. From these
searches, papers were included in the review if they investigated the effects of biological augmentation on Achilles tendon repair or healing. Platelet-rich plasma may assist in the
healing process of Achilles tendon ruptures, while the evidence to support its use in the treatment of chronic Achilles
tendinopathies remains insufficient. The use of growth factors
such as hepatocyte growth factor, recombinant human
platelet-derived growth factor-BB, interleukin-6, and
transforming growth factor beta as well as several bone morphogenetic proteins have shown promising results for Achilles
tendon repair. In vitro and preclinical studies have indicated
the potential effectiveness of bone marrow aspirate as well.
Stem cells also have positive effects on Achilles tendon
healing, particularly during the early phases.
Polyhydroxyalkanoates (PHA), decellularized tendon tissue,
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and porcine small intestinal submucosa (SIS) are biomaterials
which have shown promising results as scaffolds used in
Achilles tendon repair. The application of biological augmentation techniques in Achilles tendon repair appears promising;
however, several techniques require further investigation to
evaluate their clinical application.
Keywords Biologics . Platelet-rich plasma . Bone marrow
aspirate . Bone morphogenetic protein . Stem cells . Growth
factor . Scaffold . Achilles

Introduction
Injuries of the Achilles tendon can be devastating injuries with
unpredictable outcomes. The use of biologics in optimizing
clinical outcomes for Achilles tendon repairs is still in its
infancy. This is evidenced by the trivial amount of improvements made to the surgical approach of Achilles tendon repair
over the last 50 years [38]. It has been estimated that acute
Achilles tendon rupture has an incidence of 18 per 100,000
and continues to rise [40].
Unlike bone, tendon healing does not result in tissue homologous to its prior uninjured state. Instead, a fibrovascular
scar is formed which results in a tendon mechanically weaker
than the native tendon [25]. The resulting strength deficit may
increase risk for reinjury and other complications. Treatments
of Achilles tendon injuries aim to restore the properties of the
native tendon and reduce the risk of rerupture and complications. Currently, therapies utilizing biological augmentation
techniques are being investigated for potential benefits in tendon healing.
The purpose of this review was to summarize the current
findings of various therapies using biologics in an attempt to
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improve the prognosis of Achilles tendon ruptures and
tendinopathies. The review includes the use of platelet-rich
plasma (PRP), bone marrow aspirate (BMA), bone morphogenetic proteins (BMPs), stem cells, bioscaffolds, growth factors, and various combinations of these techniques.

Search strategies and criteria
A PubMed search was performed using keywords Bbiologics,
^ Bplatelet-rich plasma,^ Bbone marrow aspirate,^ Bbone morphogenetic protein,^ Bstem cells,^ Bgrowth factor,^ and
Bscaffold^ in combination with BAchilles.^ The search was
open for original manuscripts and review papers limited to
publication within the last 10 years. From these searches, papers were included in the review if they investigated the effects of biological augmentation on Achilles tendon repair or
healing. A total of 1097 papers were identified initially and
further broken down into the following categories: plateletrich plasma (PRP), 110; bone marrow aspirate concentrate
(BMAC), 4; bone morphogenic protein (BMP), 45; stem cells,
315; scaffolds, 213; growth factors, 371; and generalized reviews on biologics in tendon repair, 39.

Platelet-rich plasma
Platelet-rich plasma is defined by the American Red Cross as a
sample of plasma with a twofold or more increase in platelet
concentration above baseline levels or greater than 1.1×
106 platelets/μL [22]. PRP has been shown to have a number
of different growth factors. The high concentration of platelets
produces granules which release growth factors including
platelet-derived growth factor (PDGF), transforming growth
factor-β (TGF-β1 and TGF-β2 isomers), platelet-derived angiogenesis factor (PDAF), vascular endothelial growth factor
(VEGF), epidermal growth factor (EGF), platelet-derived endothelial growth factor (PDEGF), epithelial cell growth factor
(ECGF), and insulin-like growth factor (IGF) [68, 17]. The
resulting pool of growth factors is believed to enhance tissue
recovery and may be of particular use in areas with low intrinsic healing potentials [74]. The injection of PRP can stimulate
an inflammatory response and lead to new collagen deposition
as demonstrated in a healthy rabbit Achilles tendon model
[27]. Like other biologic therapies, the goal of PRP is to restore the injured tendon’s native properties.
Some evidence supports PRPs ability to stimulate revascularization and enhance healing at the microscopic level [68].
In a rat model, PRP injections decrease collagen fiber diameters which may indicate improved healing [15]. However, the
evidence for use in human chronic Achilles tendinopathy remains insufficient [60, 50, 74, 56]. In humans, the use of PRP
for Achilles tendinopathy is no more beneficial than the use of
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placebo treatment or control [67, 16, 62] Several studies suggesting an improvement of clinical symptoms provide weak
evidence with a lack of control groups [20, 23, 49, 51].
The effectiveness of PRP for the treatment of Achilles tendon ruptures should be distinguished from its effectiveness in
the treatment of chronic Achilles tendinopathies [68]. The
early phase of ruptured Achilles tendon healing is enhanced
in rats by PRP injection after surgery as evidenced by increased early depositions of fibrillar collagen [36]. Ruptured
rat Achilles tendons injected with PRP after surgery also show
greater maturation of tendon callus, stronger mechanical resistance, and enhanced neovascularization which could accelerate healing and promote scar tissue with an improved histological quality [45, 4, 36]. The potential benefits in humans
were demonstrated in a case study of an athlete with a partial
tear who received three PRP injections and no surgical intervention. He was able to return to playing in a full basketball
game just 75 days after the injury and remained without complications 18 months later [21]. An additional six athletes with
ruptured Achilles tendons treated with PRP after surgery recovered their range of motion earlier and took less time to
resume training as compared to athletes who underwent surgery without PRP treatment. These findings were supported
by a review of 10 relevant studies conducted by Sadoghi et al.
[60] showing a strong positive effect of PRP after Achilles
tendon rupture treatment. All PRP treatments increased proliferation, DNA levels, and GAG levels, although lower concentrations were more effective.
Other variations of PRP have been explored as well in
order to optimize the therapeutic benefits of autologous platelets. Plasma rich in growth factors (PRGF) is a type of
leukocyte-poor PRP. In vitro, PRGF has a positive effect on
tenocyte growth and migration [72]. A recent animal study of
PRGF in surgically treated Achilles tendons resulted in histologically superior tendon repair compared to controls. Plateletrich clot releasate (PRCR) is the acellular serum product extruded from PRP with activated platelets. In a rat Achilles
tendon model, PRCR induces tenocyte differentiation while
inhibiting the differentiation of adipocytes, chondrocytes, and
osteocytes believed to impede on tendon healing [10].

Bone marrow aspirate
Bone marrow aspirate concentrate (BMAC) is produced by
density gradient centrifugation of bone marrow usually aspirated from the iliac crest although actual stem cell numbers are
less than 0.01 % or 1/100,000 nucleated cells. Its major function is to deliver mesenchymal stem cells (MSCs) to the injury
site, and like PRP, BMAC is also rich in platelets and therefore
growth factors [66]. In vitro studies have shown an increase in
cell proliferation in Achilles tendon scaffolds seeded with
bone marrow aspirate as compared to previously cultured
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human bone marrow stem cells [8]. A recent preclinical
study found transected rat Achilles tendons injected
with bone marrow cells display greater failure load than
tendons treated with MSCs or control. By 28 days after
surgery, the failure load for rat Achilles tendons treated
with bone marrow cells is equal to that of uninjured
tendon [55]. The further investigation of the use of
BMAC in a human Achilles tendon is warranted.

Bone morphogenetic proteins
Bone morphogenetic protein-12
Also known as growth and differentiation factor-7 (GDF-7),
bone morphogenetic protein-12 (BMP-12) induces the formation of tendon and ligament-like tissue and is capable of promoting differentiation of stem cells into tenocytes [46]. These
properties have sparked interest in its potential use for tendon
healing. Majewski et al. [46] used a novel delivery method of
BMP-12 by utilizing a genetically modified muscle flap on
transected rat Achilles tendons. The administration of BMP12 increased maximum failure load, tendon stiffness, organization of collagen, and size of the rupture callus as compared
with controls. Combining BMP-12 with BMP-13 in a
transected rat Achilles tendon model results in an increased
rate of cellular infiltration, increased tissue volume, and
altered levels of mRNA known to be involved in tendon
repair [32].
Interestingly, the addition of BMP-12 to rat Achilles tendons does not affect growth factor expression [28]. This may
explain why genetically engineered knockout mice without
BMP-12 showed insignificant effects on the composition
and ultrastructure of Achilles tendons. Another possible explanation could be the overcompensation of other BMP/GDF
family members [48].
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Bone morphogenetic protein-7
Also known as osteogenic protein-1 (OP-1), bone morphogenetic protein-7 (BMP-7) has various effects on other members
of the BMP and GDF families in vitro. Animal studies have
shown the ability of BMP-7 to induce cartilage and bone formation as well as promote tendon healing and repair in rats
[79]. On the contrary, in a review conducted by Aspenberg
[3], BMP-7 was said to reduce the strength of tendon and
predominantly support bone growth at the site of the injured
tendon. The inconsistent results may be a result of BMP-7’s
involvement in the complex regulation of expression patterns
for members of the BMP and GDF families involved in Achilles tendon repair.
Bone morphogenetic protein-14
Also known as growth and differentiation factor-5 (GDF-5),
bone morphogenetic protein-14 (BMP-14) is a member of the
transforming growth factor superfamily. It plays a role in tendon collagen organization at both the cellular and gene levels.
However, its ability to interact with a large number of receptors causes its exact mechanism of action on cells to remain
uncertain [37]. It has been shown to promote Achilles tendon
healing through various delivery modalities in animal studies.
BMP-14 will induce neotendon formation when injected ectopically and increase the tensile strength of the tendon when
injected directly into the tendon defect [7]. When introduced
into rat Achilles tendon fibroblasts, GDF-5 induced extracellular matrix (ECM) synthesis and cellular proliferation. It also
increased the expression of ECM and cell adhesion-related
genes [37].
Multiple delivery methods of GDF-5 in animal studies
have shown promising results. Adenoviral gene transfer of
GDF-5 successfully resulted in the overexpression of GDF-5
in a rat model and led to increased tensile strength without
adverse immunological response [59]. The use of GDF-5coated sutures also led to improved early tendon healing at
3 weeks after surgery [18].

Bone morphogenetic protein-2
The overexpression of bone morphogenetic protein-2 (BMP2) in the MSC line C3H10T1/2 results in differentiation to
bone or cartilage. When coexpressed with the intracellular
protein Smad8, BMP-2 induces new tendon formation and
blocks the differentiation of MSCs into cartilage and bone
tissues. Achilles tendon defects in rats treated with Smad8/
BMP-2-engineered MSCs show accelerated early recovery
of biomechanical properties as indicated by effective stiffness
[57]. Furthermore, the use of BMP-2 in fibrin glue for the
repair of a bone Achilles tendon injury in rats accelerates
healing and improves the biomechanical and histological
properties of the tissue [39].

Stem cells
Mesenchymal stem cells have shown promising results for the
treatment of numerous Achilles tendon injuries including
tendon-bone healing [33, 54]. The enhancement of repair is
hypothesized to be a result of various pathways the MSCs
influence along with their anti-apoptotic effect [64]. In addition, the ability to differentiate into tenocytes may be beneficial. There is evidence that the greatest effects of MSCs occur
in the early phases of the healing process. In a study of rabbit
Achilles tendon model, improved collagen fiber organization
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was observed in tendons treated with MSCs at 3 weeks, but no
significant differences were observed later in the healing process [11].
The optimal culturing and delivery methods for MSCs is
important to explore when considering treatment with MSCs.
Several studies have looked at MSC-coated sutures as a delivery method. This technique is meant to alleviate the concern of
an Bacellular zone^ created when sutures are placed through
tendon tissue. Yao, Korotkova, and Smith [78] were able to
successfully adhere stem cells to sutures and survive the trauma of being passed through tendinous tissue. Using fluorescent microscopy, the stem cells were observed proliferating
along the suture and entering the rabbit Achilles tendon while
remaining metabolically active. A preclinical study comparing
repair with the direct injection of MSCs and repair using sutures with MSCs showed superior results histologically for the
suture group. Both groups had a significantly greater ultimate
failure strength than control group [1].
One technique used to modify the effects of MSCs is to
expand them under hypoxic conditions. Hypoxic MSCs show
increased proliferation rate and differentiation potential. After
transplantation, hypoxic MSCs display improved migration
and engraftment while secreting more cytokines and growth
factors than MSCs grown under normoxic conditions. When
used in animal studies, ultimate failure load was significantly
greater in rat Achilles tendons treated with hypoxic MSCs as
compared to normoxic MSCs and controls at 2 and 4 weeks
after surgery [31].
Another way to manipulate MSCs for tendon repair is to
use genetically modified MSCs. The zinc finger transcription
factor EGR1-producing MSCs increased the formation of
tendon-like tissues in a rat Achilles tendon model [26]. Additionally, transected rat Achilles tendons treated with Smad8/
BMP-2-engineered MSCs display accelerated early recovery
of biomechanical properties with greater elasticity and smaller
cross-sectional areas [57]. Further investigation into genetically engineered MSCs should aim to produce an
optimal combination of growth factors and cytokines
involved in tendon repair.
Combining the concept of platelet-rich therapies with MSC
treatment may also be of interest for tendon repair. Chen et al.
[10] found that platelet-rich clot releasate combined with rat
tendon stem cells facilitated the proliferation and differentiation of tenocytes and actively suppressed the differentiation of
cell types known to impede healing such as adipocyte, chondrocyte, and osteocyte lineages.
Alternate methods for culturing MSCs have been explored
as well. For example, adipose-derived stem cells (ASCs) may
be just as effective as other MSCs as measured by their
multipotency and proliferative efficiency. Also, ASC may
have a higher concentration of the pluripotent stem cells (2
vs. .01 %) compared to BMAC. ASCs increase the tensile
strength of healing rabbit Achilles tendons while increasing
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collagen type I, VEGF, and fibroblast growth factor (FGF).
However, transforming growth factor beta (TGF-β) is decreased by ASC treatment and the complex interactions between ASCs, growth factors, and their effects on tendon
healing should be further explored [73]. Another alternative
method for stem cell cultivation is to isolate circulating stem
cells from the peripheral blood. When seeded on a biodegradable scaffold, MSCs collected using this method improved
biomechanical properties and histological organization in
healing rat Achilles tendons [14].
Despite the majority of findings suggesting stem cell therapies enhance tendon repair, Kraus et al. [41] found a lack of
evidence to support the use of stem cells as a beneficial treatment in Achilles tendon repair and even suggested that it may
lead to negative outcomes. At 28 days after rat Achilles tendons were ruptured, the groups receiving MSCs displayed
inferior biomechanical testing as compared to the control
group. These results indicate the need for a more critical evaluation of the efficacy of MSC therapies for tendon repair.

Scaffolds
Finding an effective scaffold for tendon tissue engineering has
been an area of study which has received significant attention.
Various materials have been examined including natural materials such as collagen or silk and manufactured materials
such as synthetic polymers. In some cases, a hybrid of both
natural and manufactured materials have been studied with the
belief that it would promote cellular in growth while providing
mechanical support for the remodeling of the tendon [76].
Aside from scaffold material, properties such as the scaffold
length and whether it underwent prior mechanical stimulation
can also affect the ultimate stiffness of the repaired tendon
[53]. An optimal material for Achilles tendon repair would
allow natural and fast bridging of tendinous defects as well
as organized collagen-rich tissue with complete incorporation
of the material within 8 weeks [69]. Another important feature
of scaffold material may be the release of chemotactic molecules upon degradation to promote the recruitment of progenitor cells [6].
Polyhydroxyalkanoates (PHA) may serve as a good option
for scaffold material in tendon repair. They are part of a family
of biopolymers consisting of polyesters produced in nature by
microorganisms as to store energy and carbon. Specifically,
poly(3-hydroxybutyrate-co-3-hydroxyhexanoate) (PHBHHx)
is known to be compatible with many mesenchyme-derived
cell types and has adaptable mechanical properties along with
delayed biodegradability [76]. In an animal study conducted
by Webb et al. [76], PHBHHx scaffold showed superior mechanical properties and histological results for rat Achilles
tendon repair in comparison to controls.
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Another option being investigated is the use of
decellularized tendon tissue as a scaffold. This type of scaffold
is naturally derived and it preserves the native ultrastructure,
biochemical composition, and tensile strength of the tendon
extracellular matrix (ECM). Furthermore, 93 % of proteoglycans and growth factors found in native tendon ECM are preserved. These scaffolds can be prepared by repetitive freeze/
thaw of the tendon and nuclease treatment. In vitro, the
decellularized tendon slices were able to facilitate repopulation and attachment of NIH-3T3 fibroblasts [52]. Looking at
decellularized Achilles tendon-bone grafts in vivo, Farnebo
et al. [19] noted the enhancement of mechanical properties
and reduced immune response in a rat Achilles tendon model
as compared to an untreated tendon-bone graft. Decellularized
porcine tendon can also be recellularized with human
tenocytes [44].
The application of acellular tissue derived from humans
has been investigated for use in Achilles tendon healing as
well. Acellular human dermal allograft, GraftJacket® (Wright
Medical Technology, Inc, Arlington, TN, USA), showed significant improvement in mechanical strength and stiffness in
repaired Achilles tendons of human cadavers [5]. Further retrospective studies indicate a desirable return-to-activity time
without complications for patients treated with GraftJacket®
for Achilles tendon rupture [42, 43]. However, the retrospective studies were conducted in a small number of patients and
lacked reliable statistics for comparison of normal rerupture
rates and return-to-activity time.
Biomaterials from other animals have also been tested as
tendon scaffolds. Xenograft scaffolds in addition to suture
repair have shown enhanced tendon repair in vitro compared
to suture repair alone [77]. Porcine small intestinal submucosa
(SIS) has been used clinically as a scaffold material for tissue
reconstruction in many body systems. Preclinical animal studies have indicated that ECM from SIS is capable of being
remodeled into tendon tissue [24]. SIS retains several biologically active growth factors including VEGF, TGF-β, and
FGF which likely contributes to the behavior and migration
of cells into the scaffold [81]. Animal studies have shown the
rapid degradation of SIS after implantation with 60 % of the
mass lost after 1 month and complete resorption 3 months
after surgery. By 90 days, the ECM consists of dense collagenous tissue very similar to native tendon in terms of cellularity, vascularity, and organization [24]. Another advantage of
SIS is its ability to recruit a population of marrow-derived
cells involved in the long-term remodeling process [81].
Suckow et al. [69] showed porcine renal capsule matrix
(RCM) may yield similar results to porcine SIS for use as
scaffold material in Achilles tendon repair.
Scaffolds can be augmented and be potentially enhanced
by the addition of exogenous factors. Adding exogenous stromal cell-derived factor-1 alpha (SDF-1 alpha) to a silkcollagen scaffold will improve the biomechanical properties
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of the healing tendon, increase recruitment of fibroblast-like
cells, decrease accumulation of inflammatory cells, and enhance endogenous production of SDF-1 alpha and tendon
ECM in a rat model. Scaffolds may also be enhanced by the
addition of platelet-rich fibrin matrix (PRPFM) into the gap
between the two ends of a ruptured tendon supported by a
scaffold. PRPFM is produced from centrifuged autologous
blood and its benefits include increased growth factors, cytokines, and hemostatic factors [61].

Scaffolds + stem cells
In order to optimize the benefits of biologic therapies, it may
be advantageous to combine their applications. By seeding
scaffolds with stem cells, the remodeling process can be structurally supported while increasing potential for migration and
differentiation into tenocytes. Human embryonic stem cells
(hESCs) alone are inadequate for optimal tendon regeneration.
However, when seeded in a knitted silk-collagen scaffold,
hESCs are able to differentiate into tenocytes and enhance
tendon regeneration by modifying the healing environment.
The environment-modifying capabilities of hESCs occur
through the secretion of various cytokines, ECM, and growth
factors [9].
Scaffolds must be made from a material which can adequately deliver stem cells to the healing Achilles tendon. Conventional surgical mesh is capable of delivering MSCs to the
injured Achilles tendon and enhancing early functional recovery as demonstrated in a rat model [63]. When dealing with
scaffolds made from biomaterial, decellularized tendinous
matrices are preferable over bone or dermis matrices because
stem cells are more likely to differentiate into tenocyte lineages and have osteogenic inhibition [80]. Extracellular matrix
from porcine SIS is an example of a biomaterial capable of
recruiting a population of stem cells to participate in the tendon remodeling [81].
There are additional factors other than scaffold material
which impact the scaffold’s ability to effectively deliver stem
cells. For example, if cell-to-collagen ratio is too high, the
cells can become damaged by excessive cell traction forces
[34]. Finding the optimal cell-to-collagen ratio could improve
the delivery of stem cells to the healing tendon. In addition to
the concentration of ECM components, the precise spatial
arrangement of the molecules affects the delivery of MSCs.
The spatial arrangement of collagen fibrils can be modified by
the angle at which tendinous scaffolds are carved. Longitudinal tendon slicing promotes favorable seeded-cell morphogenesis and differentiation [71].
A study conducted by Pietschmann et al. [58] showed that
scaffolds seeded with MSCs may be less effective than scaffolds loaded with tenocytes. Sixteen weeks after repair, rat
Achilles tendons treated with scaffolds seeded with tenocytes
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had greater failure strength/cross-section ratio than those treated with scaffolds seeded with MSCs or controls.

Growth factors
Basic fibroblast growth factor
Basic fibroblast growth factor (bFGF) has the ability to increase collagen type I and type III production which has led
to interest in its use in tendon-healing therapy. In intrinsic
tendon healing leading to scar formation, there is an altered
type I: type III collagen ratio. Strategies to improve the native
tissue collagen ratios is a goal of functional tendon repair.
However, lentiviral bFGF transduction combined with MSCs
in an animal model had negligible effects on tendon remodeling. A possible explanation is the ability of MSCs alone to
produce sufficient bFGF required for tendon remodeling making the additional bFGF transduction unnecessary [41].
Hepatocyte growth factor
Hepatocyte growth factor (HGF) is found in PRP and is
known to have anti-inflammatory effects. In vitro and
in vivo animal studies have suggested the anti-inflammatory
effects of PRP are a result of the high concentration of HGF
[82]. It is hypothesized that HGF can reduce scar formation in
tendon healing by inhibiting the overexpression of ECM and
reducing transforming growth factor beta-1 (TGF-β1)-induced myofibroblast differentiation. These effects of HGF
have been demonstrated in a rat Achilles tendon model [12].
Recombinant human platelet-derived growth factor-BB
Recombinant human platelet-derived growth factor-BB
(rhPDGF-BB) accelerates tendon healing through a variety
of mechanisms. In ruptured tendon animal models, rhPDGFBB improves mechanical strength and range of motion
through increased matrix remodeling, collagen synthesis, vascularity, and cell proliferation [65, 13]. Its effects are thought
to be best when administered over time which has created
interest in the development of a delivery method that will
allow for optimum doses over the right time period into the
site of repair. Promising methods of delivery include rhPDGFBB-coated sutures and mesoporous silica nanoparticles
(MSN) [13, 70].
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of the healing tendon making treatment with TGF-β an important area of investigation [30]. Treatment with TGF-beta1
cDNA-transduced BMSCs grafts, injections of TGF-β, and
delivery of TGF-β by adenovirus-modified muscle grafts
have shown promising results in rat Achilles tendon models
[47, 35, 29]. As early as 2 weeks postoperatively, the repaired
tissue treated with TGF-β has histological appearance similar
to that of native tendon [47]. TGF-β therapy can increase
mechanical strength of the healing Achilles tendon by the
regulation of collagen synthesis, up-regulation of cross-link
formation, and enhanced matrix remodeling [29].
Interleukin-6
The ability of interleukin-6 (IL-6) to stimulate the synthesis of
collagen has led to the consideration of IL-6 acting as a growth
factor. The interstitial concentrations of IL-6 in the
peritendinous region around the Achilles tendon increase
drastically upon exercise, or mechanical loading. This led to
an interest in IL-6’s ability to transform mechanical loading
into collagen synthesis. In vivo study found that the infusion
of IL-6 into the peritendinous tissue around the Achilles tendon resulted in increased local collagen synthesis with or
without exercise [2]. Future studies should consider the use
of IL-6 for Achilles tendon repair and the effects of mechanical stimulation on biomaterials used for repair.
Combinatory use of growth factors
Several of the growth factors previously discussed in addition
to others such as VEGF, cartilage-derived morphogenetic
protein-2 (CDMP-2), and insulin-like growth factor-1 (IGF1) have shown positive effects when applied individually to
Achilles tendons using a variety of delivery methods [3, 75].
Konerding et al. [40] hypothesized an improvement of longterm outcomes in Achilles tendon repair from the use of the
short-term application of key mitogenic and angiogenic
growth factors in a rabbit model. However, the use of VEGF,
bFGF, and PDGF administered peritendinously had only a
marginal impact on the therapeutic outcome of Achilles tendon repair. The dosing and timing of the growth factors used
are possible reasons for their minimal effects. All three of the
chosen growth factors also require heparin sulfate proteoglycans (HSPG) in order to bind to their respective receptors. The
effects of injury on HSPGs may cause exogenous growth
factor therapy to become an ineffective treatment.

Transforming growth factor-β
Transforming growth factor-β (TGF-β) regulates the differentiation and proliferation of cells and causes an increase in
collagen I and collagen III production from tendon cells. Collagen fibers are largely responsible for the mechanical strength

Discussion
The appropriate treatment for Achilles tendon ruptures and
chronic Achilles tendinopathies remains a clinical challenge.
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Despite major advances in surgical procedures and techniques
in other areas of orthopedics, the approach to treatment of the
Achilles tendon seems to lag behind. Biological augmentations have shown promising results in their application to a
variety of pathologies and may be an integral part of optimizing Achilles tendon healing and repair. However, most of this
is lab research, and we are still awaiting clinical trials to evaluate efficacy in vivo.
Platelet-rich plasma is capable of improving the healing
process of Achilles tendon ruptures as evidenced by numerous
studies including clinical trials. However, a majority of studies
show that there remains insufficient evidence to support the
use of PRP in the treatment of chronic Achilles
tendinopathies.
The mechanism by which PRP is believed to accelerate
healing involves its high concentration of growth factors.
The use of growth factors such as HGF, rhPDGF-BB, IL-6,
and TGF-β in Achilles tendon repair has shown promising
results. Bone morphogenetic proteins such as BMP-12,
BMP-2, BMP-7, and BMP-14 have also shown positive results for the biological augmentation of Achilles tendon repair.
In vitro and preclinical studies have indicated the potential
effectiveness of bone marrow aspirate as well. The further
investigation of these techniques in a clinical setting is
warranted.
The way in which several of these techniques are
implemented involves the use of a scaffold material.
Finding an ideal biomaterial for Achilles tendon scaffolds remains an area of investigation. PHA,
decellularized tendon tissue, and porcine SIS are examples of biomaterials which have been shown to
accelerate Achilles tendon healing. The ability to deliver stem cells or promote the migration of stem cells
is potentially an important property for scaffolds to
possess. Substantial evidence supports the positive effects of stem cells on the early phases of Achilles
tendon healing.
The combination of different areas of biologics may be
useful in order to optimize the benefits of these techniques.
For example, bioscaffolds seeded with stem cells and stem
cells genetically engineered to produce specific growth factors
have successfully improved tendon repair. However, the complexity of some of the pathways involved in biological augmentation continues to remain a challenge in understanding
their interactions in vivo. Future investigation should focus on
finding an ideal combination of these techniques suitable for
clinical application.
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